Definitions
Sorry, no definitions found. You may find more data at nilotinib.
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word Nilotinib.
Examples
-
Nilotinib (Tasigna) to beat myeloid leukemia drug Glivec (imatinib) coming Diffuse large B-cell lymphoma drug pixantrone may get a quicker review in Europe Pancreatic cancer drug TNFerade by GenVec to get speedy approval in US Glycerol phenylbutyrate (HPN-100) granted orphan drug status by US FDA to treat hepatic encephalopathy Amitriptyline, ketamine combo NP-1 to treat neuralgia gets speedier review in US: EpiCept
DWS Pill Scribe pillscribe 2010
-
Nilotinib and dasatinib, a multi-targeted kinase inhibitor also approved for second-line therapy in CML, have different patterns of kinase selectivity, pharmacokinetics, and cell uptake and efflux properties, and thus patients may respond to one following failure of the other.
Naturejobs - All Jobs F J Giles 2010
-
Nilotinib is a highly selective Bcr-Abl inhibitor approved for imatinib-resistant chronic myeloid leukemia (CML).
Naturejobs - All Jobs F J Giles 2010
-
Jed Alexander, 31, was told by doctors he may have only five years to live if he does not receive Dasatinib or Nilotinib, which are supplied by the NHS in
-
Hematology: Nilotinib as first-line therapy for Ph+ CML
Naturejobs - All Jobs Lisa Hutchinson 2010
-
Nilotinib is an effective therapy in CML-CP and - AP following failure of both imatinib and dasatinib therapy.
Naturejobs - All Jobs F J Giles 2010
-
Data from this Phase III clinical trial, ENESTnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials of Newly Diagnosed Ph+ CML Patients), will show that Tasigna produced faster and deeper responses than Gleevec when used as first-line therapy.
unknown title 2009
-
Data from this Phase III clinical trial, ENESTnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials of Newly Diagnosed Ph+ CML Patients), will show that Tasigna produced faster and deeper responses than Gleevec when used as first-line therapy.
unknown title 2009
-
Nilotinib exposure is increased in patients with impaired hepatic function.
unknown title 2009
-
Data from this Phase III clinical trial, ENESTnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials of Newly Diagnosed Ph+ CML Patients), will show that Tasigna produced faster and deeper responses than Gleevec when used as first-line therapy.
unknown title 2009
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.